Neurocrine Cash from 2010 to 2024

NBIX Stock  USD 125.00  1.71  1.39%   
Neurocrine Biosciences Cash yearly trend continues to be fairly stable with very little volatility. Cash will likely drop to about 131.9 M in 2024. Cash is the total amount of money in the form of currency that Neurocrine Biosciences has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
1996-06-30
Previous Quarter
139.7 M
Current Value
349.1 M
Quarterly Volatility
142.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Cash Growth Pattern

Below is the plot of the Cash of Neurocrine Biosciences over the last few years. Cash refers to the most liquid asset of Neurocrine Biosciences, which is listed under current asset account on Neurocrine Biosciences balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Neurocrine Biosciences customers. The amounts must be unrestricted with restricted cash listed in a different Neurocrine Biosciences account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Neurocrine Biosciences' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Neurocrine Cash Regression Statistics

Arithmetic Mean176,991,029
Geometric Mean107,563,093
Coefficient Of Variation112.71
Mean Deviation136,740,914
Median112,279,000
Standard Deviation199,483,156
Sample Variance39793.5T
Range789.7M
R-Value0.53
Mean Square Error30614.9T
R-Squared0.29
Significance0.04
Slope23,838,379
Total Sum of Squares557109.4T

Neurocrine Cash History

2024131.9 M
2023251.1 M
2022262.9 M
2021340.8 M
2020801 M
2019112.3 M
2018141.7 M

Other Fundumenentals of Neurocrine Biosciences

Neurocrine Biosciences Cash component correlations

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Cash, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash251.1 M131.9 M
Cash And Short Term InvestmentsB1.1 B
Change In Cash-11.6 M-11 M
Free Cash Flow361.6 M379.7 M
Begin Period Cash Flow270.7 M284.2 M
Other Cashflows From Financing Activities65.3 M68.6 M
Other Non Cash Items-46.9 M-44.6 M
Total Cash From Operating Activities389.9 M409.4 M
Total Cash From Financing Activities65.3 M43.1 M
End Period Cash Flow259.1 M272.1 M
Total Cashflows From Investing Activities-159.4 M-151.4 M
Other Cashflows From Investing Activities-45.4 M-43.1 M
Cash And Cash Equivalents Changes-82.8 M-78.7 M
Cash Flows Other Operating-43.2 M-41 M
Free Cash Flow Yield 0.03  0.03 
Operating Cash Flow Per Share 3.99  4.19 
Free Cash Flow Per Share 3.70  3.89 
Cash Per Share 10.56  11.09 
Capex To Operating Cash Flow 0.07  0.08 
EV To Operating Cash Flow 33.47  35.14 
EV To Free Cash Flow 36.09  37.89 
Price To Operating Cash Flows Ratio 33.02  34.67 
Price To Free Cash Flows Ratio 35.60  37.38 
Cash Ratio 0.38  0.36 
Cash Conversion Cycle(564.12)(592.33)
Operating Cash Flow Sales Ratio 0.21  0.22 
Free Cash Flow Operating Cash Flow Ratio 0.93  0.81 
Cash Flow Coverage Ratios 2.29  2.41 
Price Cash Flow Ratio 33.02  34.67 
Cash Flow To Debt Ratio 2.29  2.41 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.